Therefore, the likelihood of urinary, rectal, sexual side effects, and secondary cancers is lower with proton. In 2010, Medicare spent $1.06 billion on conventional (X-ray) radiation therapy. That same year, Medicare spent $41.8 million on proton therapy, or less than 4% of X-ray cost.